- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Tetra Bio-Pharma announced a set of new appointments to prepare for the start of their commercial activities.
Tetra Bio-Pharma (TSXV:TBP; OTCQB:TBPMF) announced a set of new appointments to prepare for the start of their commercial activities.
As quoted in the press release:
The appointments of Dr. Anne-Sophie Courtois to the position of Vice President, Marketing effective immediately and Mr. Bernard Lessard to the position of Chief Financial Officer (CFO), effective September 18, 2017. Mr. Lessard will be replacing Mr. Sabino Di Paola as CFO of the corporation.
“I am very proud and pleased to be able to count on Dr. Courtois and Mr. Lessard as members of our executive team,” said Bernard Fortier, CEO of Tetra Bio-Pharma. “They will be playing a key role as Tetra imminently initiates its commercial activities and generates revenues in 2017. These highly skilled and experienced individuals will further strengthen our organization as we execute our strategy and refine the tactics that will position Tetra as a biopharmaceutical leader in cannabinoid-based drug discovery, with a clinical program aimed at bringing novel drugs and treatments to patients and their healthcare providers.”
Click here to read the full press release.
Source: www.marketwired.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.